Table 3.

Protocol-defined asthma exacerbations during the placebo-controlled period

	Placebo (n=116)	Lebrikizumab 37.5 mg (n=117)	Lebrikizumab 125 mg (n=112)	Lebrikizumab 250 mg (n=118)	Lebrikizumab dose groups combined (n=347)
Periostin-high patients (≥50 ng/mL), n	42	57	43	53	153
Total number of exacerbations	21	5	5	19	29
Total patient-years	20.7	26.6	21.2	24.1	72.0
Exacerbation rate per year	1.01	0.19	0.24	0.79	0.40
Rate reduction vs placebo
Absolute rate reduction	–	0.82	0.77	0.22	0.61
Percentage rate reduction (95% CI)	–	81% (35 to 97)	77% (26 to 95)	22% (−62 to 63)	60% (18 to 80)
Periostin-low patients (<50 ng/mL), n	74	60	69	65	194
Total number of exacerbations	17	9	20	14	43
Total patient-years	35.4	28.1	35.5	30.7	94.3
Exacerbation rate per year	0.48	0.32	0.56	0.46	0.46
Rate reduction vs placebo
Absolute rate reduction	–	0.16	−0.08	0.02	0.02
Percentage rate reduction (95% CI)	–	33% (−53 to 73)	−17% (−141 to 42)	5% (−114 to 59)	5% (−81 to 47)